UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):December 6, 2016
| | FORTRESS BIOTECH, INC. | |
| | (Exact Name of Registrant as Specified in Charter) | |
| Delaware | 001-35366 | 20-5157386 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| 2 Gansevoort Street, 9th Floor, New York, New York | 10014 |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code:(781) 652-4500 |
| |
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
Filed herewith, as Exhibit 99.1, is Fortress Biotech, Inc.’s Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September 30, 2016.
Fortress Biotech, Inc. is filing this Current Report on Form 8-K for the sole purpose of incorporating the contents of this report, including Exhibit 99.1 filed herewith, in the Company’s Registration Statement on Form S-3 filed with the SEC on August 18, 2016, as amended on November 29, 2016 (Registration No. 333-213199).
Item 9.01. Financial Statements and Exhibits.
| | Exhibit No. | | Description | |
| | | | |
| | 99.1 | | Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September 30, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | FORTRESS BIOTECH, INC. |
| | | |
| | | |
| Date: December 6, 2016 | /s/ Lindsay A. Rosenwald | |
| | Name: | Lindsay A. Rosenwald |
| | Title: | Chairman, President and Chief ExecutiveOfficer |
| | | | |
